IRIS
SANTONI, MATTEO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.021
AS - Asia 3.772
EU - Europa 3.681
SA - Sud America 812
AF - Africa 261
OC - Oceania 9
Continente sconosciuto - Info sul continente non disponibili 5
Totale 18.561
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.862
SG - Singapore 1.302
RU - Federazione Russa 722
VN - Vietnam 708
BR - Brasile 650
CN - Cina 636
UA - Ucraina 476
IT - Italia 426
SE - Svezia 392
IE - Irlanda 389
DE - Germania 370
HK - Hong Kong 362
FR - Francia 207
TR - Turchia 203
FI - Finlandia 188
GB - Regno Unito 167
DK - Danimarca 158
CI - Costa d'Avorio 151
IN - India 139
KR - Corea 103
CA - Canada 95
BD - Bangladesh 62
AR - Argentina 61
NL - Olanda 43
JP - Giappone 41
ID - Indonesia 39
MX - Messico 37
PL - Polonia 36
ZA - Sudafrica 36
IQ - Iraq 30
CO - Colombia 25
MA - Marocco 24
EE - Estonia 23
EC - Ecuador 22
PK - Pakistan 22
BE - Belgio 19
PH - Filippine 19
ES - Italia 18
VE - Venezuela 15
UZ - Uzbekistan 13
EG - Egitto 10
PY - Paraguay 10
SA - Arabia Saudita 10
TN - Tunisia 10
MY - Malesia 9
AT - Austria 8
AZ - Azerbaigian 8
CL - Cile 8
DZ - Algeria 8
IL - Israele 8
LB - Libano 8
PE - Perù 8
AU - Australia 7
BO - Bolivia 7
KE - Kenya 7
KZ - Kazakistan 7
CZ - Repubblica Ceca 6
DO - Repubblica Dominicana 6
PS - Palestinian Territory 6
TT - Trinidad e Tobago 6
EU - Europa 5
JO - Giordania 5
NP - Nepal 5
AL - Albania 4
BY - Bielorussia 4
CH - Svizzera 4
LT - Lituania 4
SY - Repubblica araba siriana 4
UY - Uruguay 4
AE - Emirati Arabi Uniti 3
CR - Costa Rica 3
ET - Etiopia 3
GR - Grecia 3
TH - Thailandia 3
AO - Angola 2
BG - Bulgaria 2
BN - Brunei Darussalam 2
HN - Honduras 2
HR - Croazia 2
JM - Giamaica 2
KG - Kirghizistan 2
KW - Kuwait 2
LU - Lussemburgo 2
MU - Mauritius 2
NG - Nigeria 2
NI - Nicaragua 2
OM - Oman 2
RS - Serbia 2
TW - Taiwan 2
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BT - Bhutan 1
CY - Cipro 1
GA - Gabon 1
GD - Grenada 1
GE - Georgia 1
GP - Guadalupe 1
GT - Guatemala 1
GY - Guiana 1
IM - Isola di Man 1
Totale 18.543
Salva come PNG Salva come JPEG
Città #
Ashburn 1.546
Singapore 886
Chandler 857
Fairfield 705
Des Moines 687
Dallas 542
Jacksonville 529
Dublin 387
Wilmington 381
San Jose 369
Hong Kong 357
Boardman 317
Woodbridge 306
Seattle 273
Houston 255
New York 248
Ho Chi Minh City 228
The Dalles 197
Cambridge 195
Hanoi 160
Lawrence 159
Princeton 159
Beijing 157
San Mateo 153
Abidjan 151
Lauterbourg 140
Los Angeles 132
Ann Arbor 126
Moscow 113
Centro 98
Munich 89
San Diego 78
Council Bluffs 66
Helsinki 65
Pune 59
Hefei 53
São Paulo 49
Da Nang 47
Orem 47
Vancouver 45
Columbus 43
Turku 43
London 42
Chicago 40
Washington 40
Turin 38
Tokyo 37
Santa Clara 36
Marche 33
Buffalo 32
Haiphong 31
Warsaw 31
Frankfurt am Main 28
Brooklyn 27
Guangzhou 27
Redmond 26
Chennai 22
Falls Church 22
Shanghai 22
Atlanta 21
Montreal 21
Ancona 20
Denver 20
Norwalk 20
Johannesburg 19
Mexico City 19
Wuhan 19
San Francisco 18
Brussels 17
Rio de Janeiro 17
Belo Horizonte 16
Manchester 16
Brasília 15
Poplar 15
Rome 15
Stockholm 15
Jakarta 14
Jiaxing 14
Hải Dương 13
Tashkent 13
Amsterdam 12
Baghdad 12
Can Tho 12
Porto Alegre 12
Seoul 12
Ankara 11
Kilburn 11
Guarulhos 10
Mumbai 10
New Delhi 10
Phoenix 10
Quận Ba 10
Thái Nguyên 10
Boston 9
Curitiba 9
Dhaka 9
Elk Grove Village 9
Istanbul 9
Wuxi 9
Baku 8
Totale 12.592
Salva come PNG Salva come JPEG
Nome #
Metabolic phenotype of bladder cancer 251
Designing novel immunocombinations in metastatic renal cell carcinoma 201
Impact of VEGF, VEGFR, PDGFR, HIF and ERCC1 gene polymorphisms on thymic malignancies outcome after thymectomy 194
Sequential or Concomitant Inhibition of Cyclin-Dependent Kinase 4/6 Before mTOR Pathway in Hormone-Positive HER2 Negative Breast Cancer: Biological Insights and Clinical Implications 194
Predicting future cancer burden in the United States by artificial neural networks 186
BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: Molecular diagnostics and possible targets for personalized therapies 185
Lgr5 expression, cancer stem cells and pancreatic cancer: Results from biological and computational analyses 177
Biological issues with cabozantinib in bone metastatic renal cell carcinoma and castration-resistant prostate cancer 176
Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical Applications 176
Computational analysis of the mutations in BAP1, PBRM1 and SETD2 genes reveals the impaired molecular processes in Renal Cell Carcinoma 170
Biomarkers of aggressiveness in genitourinary tumors with emphasis on kidney, bladder, and prostate cancer 170
Bone metastases in patients with metastatic renal cell carcinoma: Are they always associated with poor prognosis? 169
KRAS: To be or not to be targeted? Biologic and computational analyses in pancreatic adenocarcinoma 164
Thymic neoplasms: an update on the use of chemotherapy and new targeted therapies. A literature review. 163
Exploring the Spectrum of Kidney Ciliopathies 163
Pre-treatment neutrophil to lymphocyte ratio may be a useful tool in predicting survival in early triple negative breast cancer patients 161
Hyponatremia normalization as an independent prognostic factor in patients with advanced non-small cell lung cancer treated with first-line therapy 159
Adjuvant and neoadjuvant approaches for urothelial cancer: Updated indications and controversies 158
Germline and somatic mutations in prostate cancer: Focus on defective DNA repair, PARP inhibitors and immunotherapy 158
KRAS mutation status is associated with specific pattern of genes expression in pancreatic adenocarcinoma 156
HER family receptor expression and prognosis in pancreatic cancer 156
Neutrophil‑to‑lymphocyte ratio may be associated with the outcome in patients with prostate cancer 155
Pre-treatment systemic immune-inflammation represents a prognostic factor in patients with advanced non-small cell lung cancer 154
An update on investigational therapies that target STAT3 for the treatment of cancer 154
Oligometastases in Genitourinary Tumors: Recent Insights and Future Molecular Diagnostic Approach 153
Epithelial to Mesenchymal Transition in Renal Cell Carcinoma: Implications for Cancer Therapy 152
Incidence and risk of cardiotoxicity in cancer patients treated with targeted therapies 152
Tumor VEGF expression correlates with tumor stage and identifies prognostically different groups in clear cell renal cell carcinoma patients 152
Microbiome and cancers, with focus on genitourinary tumors 152
Artificial Neural Networks as a Way to Predict Future Kidney Cancer Incidence in the United States 151
Morphologic, Molecular and Clinical Features of Aggressive Variant Prostate Cancer 150
Toll like receptors and pancreatic diseases: From a pathogenetic mechanism to a therapeutic target 149
High CTLA-4 expression correlates with poor prognosis in thymoma patients 149
Contemporary best practice in the management of urothelial carcinomas of the renal pelvis and ureter 149
Metabolic Alterations in Renal and Prostate Cancer 147
The role of obesity in renal cell carcinoma patients: Clinical-pathological implications 146
Bone targeting agents in patients with metastatic prostate cancer: State of the art 144
Molecular characterization of testicular germ cell tumors using tissue microdissection 142
Adjuvant therapy in renal cell carcinoma: Is it the right strategy to inhibit VEGF? 141
Impact of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) single nucleotide polymorphisms on outcome in gastroenteropancreatic neuroendocrine neoplasms 140
Trattamento del carcinoma del pancreas. Attualità e prospettive 139
Is There a Role for Immunotherapy in Prostate Cancer? 139
PD-1 blockade therapy in renal cell carcinoma: current studies and future promises 138
An evaluation of current prostate cancer diagnostic approaches with emphasis on liquid biopsies and prostate cancer 138
Hyponatremia in cancer patients: Time for a new approach 136
AR-V7 and prostate cancer: The watershed for treatment selection? 133
IMPACT OF VEGF, VEGFR, PDGFR, HIF AND ERCC1 GENE POLYMORPHISMS ON THYMIC MALIGNANCIES OUTCOME 132
Pd-l1 inhibitors for the treatment of prostate cancer 132
Bladder cancer: molecular determinants of personalized therapy 132
Biomarkers for VEGF-Targeted Therapy in Renal Cell Carcinoma: Critical Review of Level of Evidence and Up to Date 131
Targeted therapy for solid tumors and risk of hypertension: a meta-analysis of 68077 patients from 93 phase III studies 130
An overview of emerging immunotargets of genitourinary tumors 129
Risk of hyponatraemia in cancer patients treated with targeted therapies: A systematic review and meta-analysis of clinical trials 129
Real-world data on cabozantinib in previously treated patients with metastatic renal cell carcinoma: Focus on sequences and prognostic factors 128
Current and emerging bladder cancer biomarkers with an emphasis on urine biomarkers 128
Present and future of personalized medicine in adult genitourinary tumors 127
The identification of immunological biomarkers in kidney cancers 126
New molecular targets in non clear renal cell carcinoma: An overview of ongoing clinical trials 126
Pseudocarcinomatous hyperplasia associated with primary lymphoma in the urinary bladder: a case report 124
An insight on novel molecular pathways in metastatic prostate cancer: A focus on ddr, msi and akt 124
Immunotherapy in renal cell carcinoma: latest evidence and clinical implications 123
RAS genes in colorectal carcinoma: Pathogenesis, testing guidelines and treatment implications 123
Narrative review of prostate cancer grading systems: Will the Gleason scores be replaced by the grade groups? 123
Combining radiotherapy with immunocheckpoint inhibitors or CAR-T in Renal Cell Carcinoma 122
Key role of obesity in genitourinary tumors with emphasis on urothelial and prostate cancers 120
Genitourinary tumors: Update on molecular biomarkers for diagnosis, prognosis and prediction of response to therapy 120
Clinical outcomes in patients with metastatic renal cell carcinoma receiving everolimus or temsirolimus after sunitinib 120
Neuroendocrine differentiation in prostate cancer: novel morphological insights and future therapeutic perspectives. 119
An update on immunotherapy in uro-oncology 118
Emerging concepts on drug resistance in bladder cancer: Implications for future strategies 117
Novel Therapeutic Approaches and Targets Currently Under Evaluation for Renal Cell Carcinoma: Waiting for the Revolution 117
Urinary catheters and biofilm formation 116
Healthcare cost of HER2-positive and negative breast tumors in the United States (2012–2035) 116
Circulating tumor dna testing for homology recombination repair genes in prostate cancer: From the lab to the clinic 116
Correlation of Stomatitis and Cutaneous Toxicity With Clinical Outcome in Patients With Metastatic Renal-Cell Carcinoma Treated With Everolimus 115
Renal Cell Carcinoma: genomic landscape and clinical implications 115
Emerging Immunotargets and Immunotherapies in Prostate Cancer 114
Prognostic models to predict survival in patients with advanced non-small cell lung cancer treated with first-line chemo- or targeted therapy 113
Liquid biopsy in the clinical management of bladder cancer: current status and future developments 113
New prostate cancer targets for diagnosis, imaging, and therapy: Focus on prostate-specific membrane antigen 111
Epigenetic modulations and lineage plasticity in advanced prostate cancer 111
New Frontiers in Prostate Cancer Treatment: Are We Ready for Drug Combinations with Novel Agents? 110
Treating prostate cancer by antibody-drug conjugates 110
Role of STAT3 pathway in genitourinary tumors 109
The route to personalized medicine in bladder cancer: where do we stand? 109
Agent-Based Learning Model for the Obesity Paradox in RCC 108
Prostate cancer in 2021: Novelties in prognostic and therapeutic biomarker evaluation 108
Narrative review: Predicting future molecular and clinical profiles of prostate cancer in the United States 108
Heterogeneous drug target expression as possible basis for different clinical and radiological response to the treatment of primary and metastatic renal cell carcinoma: suggestions from bench to bedside. 107
Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma 107
Update on histopathological evaluation of lymphadenectomy specimens from prostate cancer patients 107
Exploring small extracellular vesicles for precision medicine in prostate cancer 107
TNM staging towards a personalized approach in metastatic urothelial carcinoma: What will the future be like?-a narrative review 107
Emerging role of tumor-associated macrophages as therapeutic targets in patients with metastatic renal cell carcinoma. 105
Investigational therapies targeting signal transducer and activator of transcription 3 for the treatment of cancer 105
Long Non-coding RNAs in prostate cancer with emphasis on second chromosome locus associated with prostate-1 expression 105
Risk of fatigue in cancer patients treated with anti programmed cell death-1/anti programmed cell death ligand-1 agents: A systematic review and meta-analysis 105
Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer 105
PD1 and PD-L1 Inhibitors for the Treatment of Kidney Cancer: the Role of PD-L1 Assay 105
Pazopanib and sunitinib trigger autophagic and non autophagic death of bladder tumor cells. 104
Totale 13.633
Salva come PNG Salva come JPEG
Categoria #
all - tutte 89.801
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 89.801
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021620 0 0 0 0 0 0 0 0 0 277 273 70
2021/20221.346 200 208 40 24 26 142 33 65 101 118 134 255
2022/20232.865 238 271 148 214 151 879 6 156 584 13 152 53
2023/20241.401 238 34 99 162 203 362 30 41 4 30 17 181
2024/20252.547 322 206 32 16 103 88 240 92 585 239 275 349
2025/20266.507 447 509 475 541 824 466 1.335 735 662 513 0 0
Totale 18.823